AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Mechanistic modelling of time-to-positivity and colony-forming unit in tuberculosis patients on high-dose rifampicin to improve understanding of biomarker relationView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Drug effect of clofazimine on persistent mycobacteria explain an unexpected increase of bacterial load in patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Stratified dosage regimens from early bactericidal activity studies: an application to pretomanidView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019A PBPK modelling approach to simulate the rifampicin-moxifloxacin drug-drug interaction in TB patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019An assay to measure drug tolerance of M. tuberculosis in the caseous center of pulmonary lesionsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Levofloxacin target attainment analysis in MDR-TB patients: time is ripe for proactive TDMView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment AnalysisView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019PK-PD of isoniazid given at different doses among patients with MDR-TB with INH resistance mediated by inhA mutations: modeling results from ACTG A5312.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Can longitudinal PKPD biomarkers be used to forecast treatment outcome instead of M2 conversion? A population pharmacokinetic-pharmacodynamic analysis in drug sensitive pulmonary tuberculosis.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019The OptiRIF study: pharmacokinetics of high-dose rifampicin in childrenView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Exposures to first-line drugs in African and Indian children with drug-susceptible tuberculosis using novel fixed-dose-combination tablets at WHO dosing recommendation in the SHINE trialView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Ethionamide population pharmacokinetic model and Monte Carlo Simulation in patients with multidrug-resistant tuberculosisView Abstract
